Deutsche Bank’s NewAmsterdam Pharma NAMS Stock Holding History

Deutsche Bank’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.78M	Buy	199,931 +75,156	+60%	+$2.48M	﹤0.01%	1215
2026 Q1	$3.99M	Buy	124,775 +812	+0.7%	+$26.4K	﹤0.01%	1418
2025 Q4	$4.35M	Buy	123,963 +55,538	+81%	+$2.02M	﹤0.01%	1366
2025 Q3	$1.95M	Buy	68,425 +333	+0.5%	+$7.98K	﹤0.01%	1783
2025 Q2	$1.23M	Sell	68,092 -4,305	-6%	-$78.5K	﹤0.01%	1965
2025 Q1	$1.48M	Buy	72,397 +69,749	+2,634%	+$1.55M	﹤0.01%	1945
2024 Q4	$68.1K	Buy	2,648 +199	+8%	+$4.23K	﹤0.01%	3371
2024 Q3	$40.7K	Buy	+2,449	New	+$42.4K	﹤0.01%	3398

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Deutsche Bank's NAMS Position: Q2 2026 in Review

Deutsche Bank increased its NewAmsterdam Pharma (NAMS) stake by 60% in Q2 2026, buying an estimated $2.48M and bringing the position to 199,931 shares worth $6.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

Deutsche Bank first reported a position in NAMS in Q3 2024 and has held it in 8 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Deutsche Bank held 199,931 shares of NewAmsterdam Pharma worth $6.78M as of Q2 2026.
Deutsche Bank bought 75,156 NewAmsterdam Pharma shares in Q2 2026, an estimated $2.48M.
NewAmsterdam Pharma made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1215 holding.
Deutsche Bank first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 8 quarters since.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.